

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

MACS GMP CD3 pure

RRID:AB_2904535

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 170-076-124, RRID:AB_2904535

Antibody Information

URL: http://antibodyregistry.org/AB_2904535

Proper Citation: Miltenyi Biotec Cat# 170-076-124, RRID:AB_2904535

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ex vivo T cell activation

Antibody Name: MACS GMP CD3 pure

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: OKT3

Antibody ID: AB_2904535

Vendor: Miltenyi Biotec

Catalog Number: 170-076-124

Alternative Catalog Numbers: 170-076-116

Record Creation Time: 20250820T012423+0000

Record Last Update: 20250820T105051+0000

Ratings and Alerts

No rating or validation information has been found for MACS GMP CD3 pure.

No alerts have been found for MACS GMP CD3 pure.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ao Z, et al. (2026) Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15. *Cancer immunology research*, 14(6), 944.

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Zhao Q, et al. (2025) HBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3886.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T??cells. *Cell reports. Medicine*, 5(11), 101827.

Kawai A, et al. (2023) Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(24), 5069.

Nahi H, et al. (2022) Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. *Cell reports. Medicine*, 3(2), 100508.